CFU-S and short-term repopulation of EPL−/−cells transplanted into EPL−/− recipients and comparisons with double-positive cells
| Donor . | Recipient . | Femur . | PB . | Spleen . | |||
|---|---|---|---|---|---|---|---|
| Cells × 106 . | CFU-C . | WBC × 103 . | Percent 62L(−)* . | Percent Hct . | CFU-S . | ||
| 14 days after transplantation | |||||||
| +/+ | +/+ | 3.18 ± 0.44 | 772 ± 495 | 1.57 ± 0.21 | 31 ± 5 | 12.7 ± 0.33 | |
| −/− | +/+ | 3.04 ± 0.54 | 1643 ± 1567 | 1.45 ± 0.80 | 90 ± 4 | 16.7 ± 0.33 | |
| +/+ | −/− | 7.52 ± 0.07 | 1334 ± 467 | 1.36 ± 0.81 | 28 ± 6 | 18.5 ± 0.5 | |
| −/− | −/− | 4.99 ± 0.53 | 4122 ± 2151 | 2.59 ± 0.75 | 83 ± 10 | 15.3 ± 0.33 | |
| 30 days after transplantation† | |||||||
| +/+ | +/+ | 25.0 (pooled) | |||||
| −/− | +/+ | 7.23 ± 0.74 | 89.1 ± 2.0 | 52.1 (pooled) | |||
| +/+ | −/− | 14.41 ± 2.96 | 62.2 ± 7.0 | 44.5 (pooled) | |||
| −/− | −/− | 26.20 ± 4.82 | 96.7 (pooled) | 46.7 ± 1.85 | |||
| Donor . | Recipient . | Femur . | PB . | Spleen . | |||
|---|---|---|---|---|---|---|---|
| Cells × 106 . | CFU-C . | WBC × 103 . | Percent 62L(−)* . | Percent Hct . | CFU-S . | ||
| 14 days after transplantation | |||||||
| +/+ | +/+ | 3.18 ± 0.44 | 772 ± 495 | 1.57 ± 0.21 | 31 ± 5 | 12.7 ± 0.33 | |
| −/− | +/+ | 3.04 ± 0.54 | 1643 ± 1567 | 1.45 ± 0.80 | 90 ± 4 | 16.7 ± 0.33 | |
| +/+ | −/− | 7.52 ± 0.07 | 1334 ± 467 | 1.36 ± 0.81 | 28 ± 6 | 18.5 ± 0.5 | |
| −/− | −/− | 4.99 ± 0.53 | 4122 ± 2151 | 2.59 ± 0.75 | 83 ± 10 | 15.3 ± 0.33 | |
| 30 days after transplantation† | |||||||
| +/+ | +/+ | 25.0 (pooled) | |||||
| −/− | +/+ | 7.23 ± 0.74 | 89.1 ± 2.0 | 52.1 (pooled) | |||
| +/+ | −/− | 14.41 ± 2.96 | 62.2 ± 7.0 | 44.5 (pooled) | |||
| −/− | −/− | 26.20 ± 4.82 | 96.7 (pooled) | 46.7 ± 1.85 | |||
For abbreviations, see Table 1.
Percent is among total GR-1(+) cells.
Mice analyzed 30 days after transplantation were part of the original group shown at 14 days after (ie, they were transplanted with 2 × 105 cells for each from the same BM pool. There were 5-6 mice in each group.). Note the tendency for leukocytosis in selectin-deficient recipients.